ĐÁNH GIÁ HIỆU QUẢ NATRI HYALURONATE 0,1% TRONG ĐIỀU TRỊ KHÔ MẮT TRÊN BỆNH NHÂN VIÊM KHỚP DẠNG THẤP

Abstract

Objective: To evaluate the therapeutic efficacy of 0.1 % sodium hyaluronate in patients with dry eye disease (DED) associated with rheumatoid arthritis (RA). Methods: A prospective case series was conducted on 35 RA patients diagnosed with DED based on the 2010 ACR/EULAR and 2017 ADES criteria (OSDI ≥13 and TBUT <5s). All participants received 0.1% sodium hyaluronate eye drops six times daily for one month. Treatment outcomes were evaluated using the Ocular Surface Disease Index (OSDI), tear break-up time (TBUT), Schirmer I test, and Oxford grading scale. Results: The mean age was 55.54 ± 8.81 years, with 88.6% female participants. After one month, the mean OSDI score improved significantly from 27.75 ± 7.59 to 20.91 ± 9.53 (p < 0.001), with a treatment response rate of 74.3%. Mean changes in TBUT (-0.52 ± 1.59 s), Schirmer I (-0.89 ± 2.93 mm), and Oxford score (0.54 ± 1.75) were observed; except for TBUT (p = 0.029), the other changes were not statistically significant (p > 0.05). Univariate logistic regression showed that active RA status was associated with higher odds of non-response to treatment (OR = 5.4; 95% CI 1.06–27.83; p = 0.043). Conclusion: Topical 0.1% sodium hyaluronate significantly improved subjective symptoms and TBUT in RA-related DED, with a 74.3% response rate, but did not produce significant changes in objective ocular signs such as Schirmer I or Oxford score. Active RA status was associated with poor treatment response.